A top US Food and Drug Administration (FDA) enforcement official announced that the agency conducted more unannounced drug inspections in India and China in FY 2026 compared to the previous year.

The increase is attributed to an effort by the agency to increase unannounced foreign inspections to achieve inspection parity between domestic and international facilities.

“For generic drugs and biosimilars, this is not an abstract policy issue. The manufacturing network serving US patients is global, and pharmaceuticals serving the same market should be held to the same expectations. That is why the FDA has substantially increased the use of unannounced inspections overseas,” Elizabeth Miller, associate commissioner for inspections and investigations at FDA’s Office of Inspections and Investigations, said during a presentation at the Association for Accessible Medicines (AAM) GRx+Biosims conference on Tuesday...[RAPS]